-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to NMPA or corporate announcements, 48 new drugs will be approved for marketing in 2021, including 21 small molecule drugs, 9 monoclonal antibodies/proteins, 2 cell therapies, 4 vaccines, and 12 traditional Chinese medicines
21 small molecule drugs
Small molecule drugs are still the most approved drug type, with a total of 21 products approved
9 mAbs/proteins
The development of domestic antibody drugs has begun to enter the harvest season: 4 PD-(L)1 mAbs developed by 4 domestic companies, Zhongshan Kangfang Bio, Yuheng Bio, Sichuan Lukangrui Pharmaceutical, and CStone Pharmaceutical have been approved for marketing.
2 CAR-T therapies
In 2021, two CD19-targeting CAR-T cell therapies developed by Fosun Kite and WuXi Junuo were approved, opening a new era of cell therapy in China
4 new crown vaccine antibodies
The global spread of the new crown pneumonia has not caused the country to relax its vigilance
12 Traditional Chinese Medicines
The development of chemical and biological drugs has made rapid progress in recent years, but the prevention and treatment of some chronic diseases has not been significantly improved
